 Michael DiStefano
Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Negotiating | 5 | 2025 | 34 | 2.610 |
Why?
| | Morals | 4 | 2024 | 79 | 2.380 |
Why?
| | Medicare | 6 | 2025 | 904 | 2.320 |
Why?
| | Technology Assessment, Biomedical | 7 | 2026 | 45 | 1.900 |
Why?
| | Cost-Benefit Analysis | 8 | 2025 | 644 | 1.680 |
Why?
| | Direct-to-Consumer Advertising | 2 | 2024 | 8 | 1.600 |
Why?
| | Medicare Part D | 3 | 2023 | 23 | 1.560 |
Why?
| | Drug Costs | 6 | 2026 | 117 | 1.440 |
Why?
| | Alzheimer Disease | 3 | 2024 | 630 | 1.420 |
Why?
| | Prescription Drugs | 2 | 2023 | 111 | 1.270 |
Why?
| | Health Priorities | 3 | 2024 | 41 | 1.080 |
Why?
| | Drug Industry | 2 | 2026 | 49 | 0.970 |
Why?
| | Health Facility Closure | 1 | 2025 | 8 | 0.920 |
Why?
| | Drug Compounding | 1 | 2026 | 107 | 0.910 |
Why?
| | Anti-Obesity Agents | 1 | 2026 | 67 | 0.900 |
Why?
| | Pharmacies | 1 | 2025 | 40 | 0.890 |
Why?
| | Community Pharmacy Services | 1 | 2025 | 46 | 0.880 |
Why?
| | Glucagon-Like Peptides | 1 | 2026 | 71 | 0.860 |
Why?
| | Bioethics | 2 | 2024 | 25 | 0.840 |
Why?
| | Health Care Rationing | 1 | 2024 | 56 | 0.840 |
Why?
| | Comparative Effectiveness Research | 2 | 2025 | 169 | 0.810 |
Why?
| | Social Values | 2 | 2023 | 40 | 0.790 |
Why?
| | United States | 19 | 2026 | 16126 | 0.750 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 123 | 0.750 |
Why?
| | Medicare Part C | 1 | 2023 | 36 | 0.730 |
Why?
| | Public Opinion | 1 | 2022 | 62 | 0.690 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 171 | 0.660 |
Why?
| | Health Equity | 1 | 2023 | 133 | 0.640 |
Why?
| | Hypoglycemic Agents | 2 | 2026 | 1399 | 0.600 |
Why?
| | Qualitative Research | 2 | 2025 | 1683 | 0.600 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2024 | 701 | 0.570 |
Why?
| | Social Justice | 1 | 2019 | 81 | 0.560 |
Why?
| | Humans | 36 | 2026 | 145783 | 0.480 |
Why?
| | Social Media | 1 | 2019 | 167 | 0.470 |
Why?
| | Wearable Electronic Devices | 1 | 2017 | 69 | 0.460 |
Why?
| | South Africa | 4 | 2023 | 266 | 0.430 |
Why?
| | Blood Glucose | 1 | 2024 | 2344 | 0.420 |
Why?
| | Public Health | 1 | 2018 | 574 | 0.380 |
Why?
| | Policy | 2 | 2024 | 149 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2026 | 2602 | 0.350 |
Why?
| | Cross-Sectional Studies | 5 | 2026 | 5925 | 0.330 |
Why?
| | Aged | 10 | 2025 | 26217 | 0.330 |
Why?
| | Economics, Pharmaceutical | 2 | 2019 | 10 | 0.300 |
Why?
| | Biosimilar Pharmaceuticals | 2 | 2026 | 28 | 0.280 |
Why?
| | Depression | 1 | 2018 | 1559 | 0.280 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3937 | 0.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 992 | 0.260 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6085 | 0.250 |
Why?
| | Oklahoma | 1 | 2026 | 22 | 0.240 |
Why?
| | Decision Making | 2 | 2024 | 982 | 0.240 |
Why?
| | Ethical Analysis | 1 | 2026 | 6 | 0.240 |
Why?
| | Cost Sharing | 1 | 2026 | 20 | 0.230 |
Why?
| | Pharmacy Technicians | 1 | 2025 | 1 | 0.230 |
Why?
| | Costs and Cost Analysis | 2 | 2023 | 221 | 0.230 |
Why?
| | Genetic Therapy | 2 | 2025 | 316 | 0.230 |
Why?
| | Utah | 1 | 2025 | 80 | 0.230 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1101 | 0.220 |
Why?
| | Biomedical Technology | 2 | 2022 | 50 | 0.220 |
Why?
| | Focus Groups | 2 | 2025 | 572 | 0.220 |
Why?
| | Cost Savings | 1 | 2024 | 86 | 0.210 |
Why?
| | Reimbursement Mechanisms | 1 | 2025 | 79 | 0.210 |
Why?
| | Germany | 1 | 2024 | 138 | 0.200 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 125 | 0.200 |
Why?
| | Medicaid | 2 | 2025 | 467 | 0.200 |
Why?
| | Medicare Part B | 1 | 2023 | 7 | 0.200 |
Why?
| | Technology | 1 | 2024 | 97 | 0.190 |
Why?
| | National Health Programs | 1 | 2023 | 23 | 0.190 |
Why?
| | Hemophilia B | 1 | 2023 | 65 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 198 | 0.190 |
Why?
| | Psychotherapy | 1 | 2024 | 182 | 0.190 |
Why?
| | Pharmacists | 1 | 2025 | 258 | 0.180 |
Why?
| | Adult | 5 | 2026 | 40881 | 0.180 |
Why?
| | Human Rights | 1 | 2022 | 19 | 0.180 |
Why?
| | Mental Competency | 1 | 2022 | 27 | 0.180 |
Why?
| | Female | 9 | 2026 | 79045 | 0.180 |
Why?
| | Health Expenditures | 1 | 2023 | 194 | 0.170 |
Why?
| | Hemophilia A | 1 | 2023 | 148 | 0.170 |
Why?
| | Drug Approval | 1 | 2022 | 93 | 0.170 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 293 | 0.170 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 208 | 0.160 |
Why?
| | Male | 9 | 2026 | 73011 | 0.160 |
Why?
| | Pressure Ulcer | 1 | 2021 | 40 | 0.160 |
Why?
| | Anemia, Sickle Cell | 1 | 2025 | 318 | 0.160 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2021 | 58 | 0.160 |
Why?
| | Patient Positioning | 1 | 2021 | 70 | 0.160 |
Why?
| | Informed Consent | 1 | 2022 | 199 | 0.160 |
Why?
| | Patient Participation | 1 | 2024 | 446 | 0.150 |
Why?
| | Middle Aged | 4 | 2026 | 36309 | 0.150 |
Why?
| | Economic Competition | 1 | 2019 | 13 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2019 | 73 | 0.150 |
Why?
| | Public Health Surveillance | 1 | 2019 | 83 | 0.140 |
Why?
| | Civil Disorders | 1 | 2018 | 8 | 0.140 |
Why?
| | Colorado | 2 | 2025 | 4556 | 0.140 |
Why?
| | Cell Phone | 1 | 2019 | 82 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2024 | 948 | 0.130 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.130 |
Why?
| | Retrospective Studies | 3 | 2024 | 17330 | 0.130 |
Why?
| | Diabetes Mellitus | 1 | 2026 | 1101 | 0.120 |
Why?
| | Developing Countries | 1 | 2019 | 317 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 890 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 1192 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2024 | 3418 | 0.120 |
Why?
| | Violence | 1 | 2018 | 281 | 0.110 |
Why?
| | Infant, Newborn | 1 | 2024 | 6465 | 0.090 |
Why?
| | Chronic Disease | 1 | 2019 | 1812 | 0.090 |
Why?
| | Cohort Studies | 1 | 2023 | 6033 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2668 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 7216 | 0.090 |
Why?
| | Young Adult | 2 | 2026 | 14254 | 0.080 |
Why?
| | Adolescent | 2 | 2026 | 22577 | 0.070 |
Why?
| | Drugs, Generic | 1 | 2026 | 28 | 0.060 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2024 | 6 | 0.050 |
Why?
| | Markov Chains | 1 | 2025 | 132 | 0.050 |
Why?
| | Models, Economic | 1 | 2025 | 62 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2026 | 381 | 0.040 |
Why?
| | Ontario | 1 | 2019 | 90 | 0.040 |
Why?
| | Japan | 1 | 2019 | 149 | 0.040 |
Why?
| | Public Policy | 1 | 2019 | 80 | 0.040 |
Why?
| | Hospitals | 1 | 2021 | 733 | 0.030 |
Why?
| | Critical Care | 1 | 2021 | 702 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8347 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11794 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 10919 | 0.010 |
Why?
| | Child | 1 | 2022 | 22740 | 0.010 |
Why?
|
|
DiStefano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|